AbbVie Tshuag poob rau hnub Wednesday tom qab lub tuam txhab tshaj tawm Thawj Tswj Hwm thiab Tus Lwm Thawj Coj Michael Severino yuav tawm mus thaum kawg lub Tsib Hlis.
X
Severino tab tom mus rau Flagship Pioneering, tus tsim biotech qab lub npe loj xws li Niaj hnub (mRNA), thiab me me players Denali Kev Kho Mob (DNLI) thiab Seres Tshuaj Kho Mob (MRCB) - rau npe ob peb. Nws yuav dhau los ua tus khub thawj coj ntawm Flagship thiab yuav ua tus thawj coj ntawm ib lub tuam txhab.
Nws tawm hauv AbbVie tom qab yim xyoo. Hauv nws lub luag haujlwm, nws tau ua lub luag haujlwm rau kev tshawb fawb thiab kev txhim kho, thiab lub koom haum ua haujlwm zoo. Severino tau ceeb toom rau AbbVie ntawm nws cov phiaj xwm rau lub Plaub Hlis 8, raws li Securities thiab Exchange Commission foob.
Nyob rau Tshuag lag luam hnub no, AbbVie Tshuag poob 4.2% rau 158.95.
AbbVie Tshuag Dives Raws li Severino Exits
Raws li CEO-tus khub, Severino yuav pab Flagship "tsim thiab txhim kho kev tsim kho tshiab hauv tib neeg kev noj qab haus huv," lub tuam txhab tau hais hauv xov xwm tshaj tawm.
Severino tau ua haujlwm hauv kev tsim tshuaj rau ntau tshaj ob xyoo lawm. Ua ntej AbbVie, nws ua haujlwm ntawm Amgen (AMGN) thiab Merck (MRK).
"Kuv zoo siab heev los ua lub luag haujlwm no thiab koom tes nrog cov pab pawg siab tshaj plaws ntawm cov kws tshawb fawb hauv ntiaj teb, cov kws tshaj lij thiab cov thawj coj ua lag luam sib sau ua ke los ntawm Flagship Pioneering," Severino tau hais hauv nqe lus sau. "Kuv tos ntsoov yuav siv kuv qhov kev paub dhau los ntawm txhua theem ntawm kev tshawb nrhiav tshuaj, kev txhim kho thiab kev lag luam ntawm Flagship, los pab ua qhov sib txawv tseem ceeb rau cov neeg mob."
Thaum lub sijhawm Severino txoj haujlwm, AbbVie ntxiv Skyrizi thiab Rinvoq, ob lub tshuaj tiv thaiv kab mob tshiab uas tuaj yeem pab ua kom poob qis hauv cov nyiaj tau los raws li Humira - lub ntiaj teb cov tshuaj muag zoo tshaj plaws - pib ntsib pheej yig dua biosimilar cov neeg sib tw hauv Teb Chaws Asmeskas Biosimilars rau Humira zoo li yuav co AbbVie Tshuag.
AbbVie kuj tau txais kev pom zoo ntawm Food and Drug Administration xyoo tas los rau cov tshuaj tiv thaiv kab mob migraine hu ua Qulipta, uas muaj peev xwm sib tw rau Biohaven Cov Tshuaj Kho Mob'((BHVN) Nurtec.
Cov xov xwm ntawm Severino txoj kev tawm mus kuj tuaj raws li AbbVie tshaj tawm 20-xyoo hnub tseem ceeb ntawm thawj FDA pom zoo rau Botox. Thaum lub sij hawm, nws tau pom zoo raws li kev kho kom zoo nkauj rau wrinkles. Tam sim no, nws kuj tau siv los kho migraines, tawm hws ntau dhau thiab lwm yam mob.
Shares Ntaus Lawv Stride Xyoo No
AbbVie Tshuag tau khiav ntawm lub xyoo no, nce ze li 30% rau cov ntaub ntawv ntawm 175.91 rau lub Plaub Hlis 8.
Severino txoj kev tawm mus tau xa cov khoom poob qis, tab sis cov khw muag tshuaj tseem nyob zoo dua nws 50-hnub thiab 200-hnub txav nruab nrab.
Bullishly, AbbVie Tshuag kuj muaj Puas Ntsuam Xyuas ntawm 95. Qhov no tso cov shares nyob rau hauv lub sab saum toj 5% ntawm tag nrho cov stocks nyob rau hauv cov nqe lus ntawm lub hauv paus thiab kev ntsuas, raws li IB Digital. cov Ntsuam Xyuas Lub Zog Muaj Zog ntawm 96 txhais tau tias AbbVie Tshuag lag luam nyob rau hauv thawj 4% nyob rau hauv cov nqe lus ntawm 12-lub hlis kev ua tau zoo.
Ua raws li Allison Gatlin ntawm Twitter ntawm @IBD_AGatlin.
KOJ UA LI CAS:
Myovant Sciences Collapses Raws li FDA Holdup Snags Nws Blockbuster Potential
Biotech Pub Spree Raws li GSK, Halozyme Tshaj Tawm Ze li $ 3 nphom hauv Deals
Xav Tau Ntau IBD Insights? Sau npe yuav Peb Ua Luam Podcast!
Tau Txais Cov Tswv Yim Npaj Los Ntawm IBD Kws Tshaj Lij Txhua Hmo Ua Ntej Qhib
IBD Tshuag Ntawm Hnub: Saib Yuav Tsum Nrhiav Li Cas, Teev Thiab Yuav Cov Khoom Zoo
Tau qhov twg los: https://www.investors.com/news/technology/abbvie-stock-breaks-its-stride-as-key-executive-departs-for-flagship/?src=A00220&yptr=yahoo